Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab.

Conclusions: IBD causes a significant burden to the Finnish healthcare system. This study provides a detailed characterization of the cost landscape of IBD and contributes to optimizing treatment strategies and healthcare resource use in the biosimilar era. PMID: 31203693 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31203693?dopt=Abstract

Source: Scandinavian Journal of Gastroenterology - June 19, 2019 Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research